GEN PROBE INC Form S-8 POS August 13, 2012

As filed with the Securities and Exchange Commission on August 13, 2012

Registration No. 333-99947

Registration No. 333-103899

Registration No. 333-105649

Registration No. 333-135493

Registration No. 333-160989

Registration No. 333-176013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-99947

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-103899

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-105649

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-135493

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-160989

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-176013

UNDER THE SECURITIES ACT OF 1933

GEN-PROBE INCORPORATED

(Exact Name of Registrant As Specified in its Charter)

Delaware (State or Other Jurisdiction of

33-0044608 (I.R.S. Employer

Incorporation or Organization)

Identification No.)

10210 Genetic Center Drive

San Diego, California (Address Of Principal Executive Offices) 92121 (Zip Code)

The 2003 Incentive Award Plan of Gen-Probe Incorporated

Gen-Probe Incorporated Employee Stock Purchase Plan

The 2002 New-Hire Stock Option Plan of Gen-Probe Incorporated

2000 Equity Participation Plan of Gen-Probe Incorporated

(Full Title of the Plans)

Glenn P. Muir

Executive Vice President, Treasurer and Assistant Secretary

Gen-Probe Incorporated

c/o Hologic, Inc.

35 Crosby Drive

Bedford, Massachusetts 01730

(Name and address of agent for service)

(781) 999-7300

(Telephone number, including area code, of agent for service)

Copies to:

Philip J. Flink, Esq.

Brown Rudnick LLP

One Financial Center

Boston, Massachusetts 02111

(617) 856-8200

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting							
company. See the definitions of	large accelerated filer,	accelerated filer	and	smaller reporting company	in Rule 12b-2 of the Exchange Act.		
(Check one):							

Large accelerated filer x Accelerated filer

Non-accelerated filer " (Do not check if a smaller reporting company) Smaller reporting company

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment (this Post-Effective Amendment) relates to the following Registration Statements of Gen-Probe Incorporated (the Company) on Form S-8 (each, a Registration Statement and collectively, the Registration Statements):

Registration Statement No. 333-99947, registering 2,413,973 shares of the Company s common stock, par value \$0.0001 per share (Company common stock), under the 2000 Equity Participation Plan of Gen-Probe Incorporated;

Registration Statement No. 333-103899, registering 200,000 shares of Company common stock under The 2002 New-Hire Stock Option Plan of Gen-Probe Incorporated;

Registration Statement No. 333-105649, registering 2,500,000 shares of Company common stock under The 2003 Incentive Award Plan of Gen-Probe Incorporated and 500,000 shares of Company common stock under the Gen-Probe Incorporated Employee Stock Purchase Plan:

Registration Statement No. 333-135493, registering 3,000,000 shares of Company common stock under The 2003 Incentive Award Plan of Gen-Probe Incorporated;

Registration Statement No. 333-160989, registering 2,500,000 shares of Company common stock under The 2003 Incentive Award Plan of Gen-Probe Incorporated; and

Registration Statement No. 333-176013, registering 2,500,000 shares of Company common stock under The 2003 Incentive Award Plan of Gen-Probe Incorporated.

On August 1, 2012, the Company was acquired by Hologic, Inc., a Delaware corporation (Hologic), pursuant to the merger of Gold Acquisition Corp., a Delaware corporation and a direct wholly owned subsidiary of Hologic (Merger Sub), with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Hologic (the Merger). The Merger was effected pursuant to the previously announced Agreement and Plan of Merger, dated as of April 29, 2012 (the Merger Agreement), by and among the Company, Hologic, and Merger Sub. Pursuant to the Merger Agreement, at the effective time of the Merger (the Effective Time), each outstanding share of Company common stock was converted into the right to receive \$82.75 in cash, without interest and less any applicable withholding taxes (the Merger Consideration), other than (i) treasury shares, (ii) shares held by the Company or any of its subsidiaries, (iii) shares held by Hologic, Merger Sub or any other subsidiary of Hologic, and (iv) shares held by stockholders who have properly demanded, exercised and perfected and not withdrawn a demand for statutory appraisal rights under Delaware law, if any.

Also at the Effective Time, each outstanding option to purchase shares of Company common stock, other than options granted on or after February 8, 2012, was cancelled in exchange for the right to receive an amount in cash equal to the excess of the Merger Consideration over the exercise price for each share subject to the applicable option, less any applicable withholding taxes. With respect to stock options granted on or after February 8, 2012, each such option (i) was assumed by Hologic and will continue to have, and be subject to, the same terms and conditions applicable to such option, and (ii) will be, or will become, exercisable for a number of shares of Hologic common stock equal to the product of (x) the number of shares that would have been issuable upon exercise of such option and (y) the Option Exchange Ratio (as defined in the Merger Agreement). With respect to each share of restricted stock, the vesting restrictions lapsed at the Effective Time and each such share became fully vested and was converted into the right to receive a cash payment in an amount equal to the product of (i) the number of shares subject to the award and (ii) the Merger Consideration. With respect to each award representing the right to receive shares of Company common stock that is subject to performance-based conditions, the performance periods thereunder terminated at the Effective Time, and 150% of the target number of shares subject to the performance award with respect to such performance periods fully vested and were converted into the right to receive a cash payment in an amount equal to the product of (i) the number of vested shares subject to the award and (ii) the Merger Consideration.

As a result of the Merger, the Company has terminated any and all offerings of securities pursuant to the Registration Statements. Accordingly, the Company hereby terminates the effectiveness of each Registration Statement and, in accordance with an undertaking made by the Company in Part II of each Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been

registered for issuance but remain unsold at the termination of the offering, removes from registration any and all securities registered but unsold under the Registration Statements as of the date hereof.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these post-effective amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Bedford, Commonwealth of Massachusetts, on August 13, 2012.

GEN-PROBE INCORPORATED

By: /s/ Glenn P. Muir Name: Glenn P. Muir

Title: Executive Vice President, Treasurer and

Assistant Secretary

Pursuant to the requirements of the Securities Act of 1933, these post-effective amendments to the Registration Statements have been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Robert A. Cascella Robert A. Cascella	President and Director	August 13, 2012
/s/ Glenn P. Muir Glenn P. Muir	Executive Vice President, Treasurer and Assistant Secretary and Director	August 13, 2012